Patent protections incentivize innovation, allowing biopharmaceutical companies to invest decades and billions of dollars in research and development to find new treatments and cures.

Brand patented medicines often have many competitors. There are no monopolies on treating a condition.

Promoting Access

IP protections lead to more treatment options for patients. In the last three years alone, 150 new treatments and cures have been approved by the FDA, and over 3,000 generic alternatives have been approved or are on the road to approval.

Today more than 90% of prescriptions for medicines are filled with generics—up from 19% 35 years ago.

Policies that undermine IP protections, such as government seizure of patent protections, are a threat to the future of new and affordable treatments and cures for patients.

Incentivizing Innovation

Without reliable patent protections for inventions, innovators couldn’t risk decades and billions of dollars in R&D to find the next cure.

Innovation shouldn’t stop once a new drug first becomes available to patients. Additional patent protections only cover enhancements to a product and allow companies to continue working to improve medicines, making them more effective for patients—whether reducing side effects or finding a new disease a medicine can treat.

Patents grant exclusive rights to new inventions for a set period, while public disclosure requires innovators to publicly share information about their inventions—allowing more generic medicines to be developed and enter the market after patent protections expire.

Upholding Commitment

The biopharmaceutical industry is committed to working every day to discover and develop new treatments and cures for patients battling diseases like Alzheimer’s, heart disease, and, most recently, COVID-19. This is made possible by America’s system of IP protections.